Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/26530
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kamposioras K | - |
dc.contributor.author | Mauri D | - |
dc.contributor.author | Papadimitriou K | - |
dc.contributor.author | Anthoney A | - |
dc.contributor.author | Hindi N | - |
dc.contributor.author | Petricevic B | - |
dc.contributor.author | Dambrosio M | - |
dc.contributor.author | Valachis A | - |
dc.contributor.author | Kountourakis P | - |
dc.contributor.author | Kopecky J | - |
dc.contributor.author | Kuhar CG | - |
dc.contributor.author | Popovic L | - |
dc.contributor.author | Chilingirova NP | - |
dc.contributor.author | Zarkavelis G | - |
dc.contributor.author | de Mello RA | - |
dc.contributor.author | Plavetić ND | - |
dc.contributor.author | Christopoulos C | - |
dc.contributor.author | Mostert B | - |
dc.contributor.author | Goffin JR | - |
dc.contributor.author | Tzachanis D | - |
dc.contributor.author | Saraireh HH | - |
dc.contributor.author | Ma F | - |
dc.contributor.author | Pavese I | - |
dc.contributor.author | Tolia M | - |
dc.date.accessioned | 2021-06-08T17:38:29Z | - |
dc.date.available | 2021-06-08T17:38:29Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | http://hdl.handle.net/11375/26530 | - |
dc.description.abstract | <jats:sec><jats:title>Introduction</jats:title><jats:p>Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.</jats:p></jats:sec> | - |
dc.publisher | Frontiers Media SA | - |
dc.rights.uri | 2 | - |
dc.subject | Covid-19 | - |
dc.subject | international | - |
dc.subject | oncology | - |
dc.subject | recommendations | - |
dc.subject | societies | - |
dc.title | Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth | - |
dc.type | Article | - |
dc.date.updated | 2021-06-08T17:38:28Z | - |
dc.rights.license | Attribution - CC BY | - |
dc.identifier.doi | https://doi.org/10.3389/fonc.2020.575148 | - |
Appears in Collections: | Faculty Publications (via McMaster Experts) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Synthesis of Recommendations From 25 Countries and 31 Oncology Societies How to Navigate Through Covid-19 Labyrinth.pdf | Published version | 489.86 kB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.